James P. Allison

119.4k total citations · 67 hit papers
487 papers, 72.3k citations indexed

About

James P. Allison is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, James P. Allison has authored 487 papers receiving a total of 72.3k indexed citations (citations by other indexed papers that have themselves been cited), including 327 papers in Immunology, 242 papers in Oncology and 49 papers in Molecular Biology. Recurrent topics in James P. Allison's work include Immunotherapy and Immune Responses (195 papers), Cancer Immunotherapy and Biomarkers (188 papers) and Immune Cell Function and Interaction (171 papers). James P. Allison is often cited by papers focused on Immunotherapy and Immune Responses (195 papers), Cancer Immunotherapy and Biomarkers (188 papers) and Immune Cell Function and Interaction (171 papers). James P. Allison collaborates with scholars based in United States, Australia and United Kingdom. James P. Allison's co-authors include Padmanee Sharma, Matthew F. Krummel, Dana R. Leach, Cynthia A. Chambers, Jedd D. Wolchok, Spencer C. Wei, Karl S. Peggs, Jackson G. Egen, Colm R. Duffy and Wendy L. Havran and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

James P. Allison

476 papers receiving 70.8k citations

Hit Papers

The future of im... 1974 2026 1991 2008 2015 2005 1996 2018 1995 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The future of immune checkpoint therapy
    2015 3.6k citations Padmanee Sharma, James P. Allison Science profile →
  2. Restoring function in exhausted CD8 T cells during chronic viral infection
    2005 3.1k citations James P. Allison et al. profile →
  3. Enhancement of Antitumor Immunity by CTLA-4 Blockade
    1996 2.9k citations James P. Allison et al. Science profile →
  4. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
    2018 2.2k citations James P. Allison et al. profile →
  5. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
    1995 1.7k citations James P. Allison et al. The Journal of Experimental Medicine profile →
  6. Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
    2015 1.7k citations Padmanee Sharma, James P. Allison profile →
  7. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
    2010 1.5k citations Michael A. Curran, Hideo Yagita∥ et al. Proceedings of the National Academy of Sciences profile →
  8. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones
    1992 1.4k citations James P. Allison et al. profile →
  9. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
    2003 1.2k citations Giao Q. Phan, James Chih‐Hsin Yang et al. Proceedings of the National Academy of Sciences profile →
  10. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
    2013 1.1k citations Tyler R. Simpson, Fubin Li et al. The Journal of Experimental Medicine profile →
  11. The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
    2009 1.1k citations James P. Allison et al. Clinical Cancer Research profile →
  12. Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells
    1993 974 citations James P. Allison et al. Science profile →
  13. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
    2012 932 citations James P. Allison, Lloyd J. Old et al. profile →
  14. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
    2017 928 citations Padmanee Sharma, Jennifer A. Wargo et al. profile →
  15. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
    2016 913 citations Jianjun Gao, Lewis Z. Shi et al. profile →
  16. Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses
    2001 834 citations James P. Allison et al. The Journal of Experimental Medicine profile →
  17. Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
    1999 824 citations James P. Allison et al. The Journal of Experimental Medicine profile →
  18. CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor Immunotherapy
    2001 797 citations Cynthia A. Chambers, James P. Allison et al. profile →
  19. Immune-Mediated Inhibition of Metastases after Treatment with Local Radiation and CTLA-4 Blockade in a Mouse Model of Breast Cancer
    2005 787 citations James P. Allison et al. Clinical Cancer Research profile →
  20. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
    2003 778 citations Thomas A. Davis, Alan J. Korman et al. Proceedings of the National Academy of Sciences profile →
  21. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.
    1996 770 citations James P. Allison et al. The Journal of Experimental Medicine profile →
  22. CTLA-4: new insights into its biological function and use in tumor immunotherapy
    2002 757 citations James P. Allison et al. profile →
  23. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis
    2015 749 citations Tsvetelina Pentcheva‐Hoang, James P. Allison et al. profile →
  24. ICOS co-stimulatory receptor is essential for T-cell activation and function
    2001 747 citations James P. Allison et al. profile →
  25. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
    2009 726 citations Karl S. Peggs, Sergio A. Quezada et al. The Journal of Experimental Medicine profile →
  26. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
    2003 695 citations Xingxing Zang, James P. Allison et al. profile →
  27. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
    2010 635 citations Sergio A. Quezada, Tyler R. Simpson et al. The Journal of Experimental Medicine profile →
  28. Immune checkpoint therapy—current perspectives and future directions
    2023 579 citations Padmanee Sharma, Sangeeta Goswami et al. profile →
  29. Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
    2014 564 citations Sumit K. Subudhi, Taha Merghoub et al. profile →
  30. The Emerging Role of CTLA-4 as an Immune Attenuator
    1997 531 citations James P. Allison et al. profile →
  31. Constitutive class I-restricted exogenous presentation of self antigens in vivo.
    1996 522 citations James P. Allison et al. The Journal of Experimental Medicine profile →
  32. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
    2013 522 citations Jedd D. Wolchok, James P. Allison et al. The Journal of Experimental Medicine profile →
  33. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells
    2003 501 citations P’ng Loke, James P. Allison Proceedings of the National Academy of Sciences profile →
  34. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
    2011 492 citations Padmanee Sharma, Jedd D. Wolchok et al. profile →
  35. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
    2008 488 citations Alan J. Korman, James P. Allison et al. Proceedings of the National Academy of Sciences profile →
  36. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
    2019 486 citations James P. Allison et al. profile →
  37. The Next Decade of Immune Checkpoint Therapy
    2021 480 citations Padmanee Sharma, Shalini S. Yadav et al. profile →
  38. Developmentally ordered appearance of thymocytes expressing different T-cell antigen receptors
    1988 464 citations James P. Allison et al. profile →
  39. Checkpoint Blockade in Cancer Immunotherapy
    2006 463 citations Alan J. Korman, Karl S. Peggs et al. profile →
  40. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
    2017 455 citations Jianjun Gao, Lewis Z. Shi et al. profile →
  41. Limited diversity of γδ antigen receptor genes of thy-1+ dendritic epidermal cells
    1988 451 citations James P. Allison et al. profile →
  42. Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody.
    1982 447 citations James P. Allison et al. profile →
  43. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer
    2017 434 citations James P. Allison et al. profile →
  44. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
    2011 410 citations Jianda Yuan, Jedd D. Wolchok et al. profile →
  45. Immune Modulation in Cancer with Antibodies
    2013 403 citations James P. Allison, Jedd D. Wolchok et al. profile →
  46. Cytotoxic T Lymphocyte Antigen-4 Accumulation in the Immunological Synapse Is Regulated by TCR Signal Strength
    2002 403 citations James P. Allison et al. profile →
  47. Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
    2015 371 citations James P. Allison, Taha Merghoub et al. profile →
  48. Co-stimulation in T cell responses
    1997 369 citations Cynthia A. Chambers, James P. Allison profile →
  49. Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
    2010 358 citations Bradley Curtis Carthon, Jedd D. Wolchok et al. Clinical Cancer Research profile →
  50. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.
    2000 355 citations James P. Allison et al. profile →
  51. B7-1 and B7-2 Selectively Recruit CTLA-4 and CD28 to the Immunological Synapse
    2004 348 citations Tsvetelina Pentcheva‐Hoang, James P. Allison et al. profile →
  52. Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
    2010 344 citations Geoffrey Y. Ku, Jianda Yuan et al. profile →
  53. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
    2006 337 citations Karl S. Peggs, Sergio A. Quezada et al. profile →
  54. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer
    1997 326 citations James P. Allison et al. Proceedings of the National Academy of Sciences profile →
  55. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome
    2007 324 citations Xingxing Zang, Padmanee Sharma et al. Proceedings of the National Academy of Sciences profile →
  56. A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer
    2007 323 citations James P. Allison et al. Clinical Cancer Research profile →
  57. Epitope Landscape in Breast and Colorectal Cancer
    2008 318 citations Karl S. Peggs, James P. Allison et al. Cancer Research profile →
  58. Monoclonal Antibodies for Cancer Therapy
    2012 298 citations James P. Allison, Jedd D. Wolchok et al. profile →
  59. The Immunobiology of T Cells with Invariant gammadelta Antigen Receptors
    1991 287 citations James P. Allison et al. profile →
  60. Response deprivation: An empirical approach to instrumental performance.
    1974 266 citations James P. Allison et al. profile →
  61. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
    2018 266 citations Anu Sharma, Sumit K. Subudhi et al. Clinical Cancer Research profile →
  62. Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
    2014 255 citations James P. Allison, Padmanee Sharma et al. Cancer Immunology Research profile →
  63. Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
    2011 254 citations Jianda Yuan, James P. Allison et al. Proceedings of the National Academy of Sciences profile →
  64. Aire-Dependent Thymic Development of Tumor-Associated Regulatory T Cells
    2013 251 citations Sven Malchow, Daniel S. Leventhal et al. Science profile →
  65. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
    2013 233 citations Jedd D. Wolchok, James P. Allison et al. profile →
  66. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
    2014 229 citations Xiaozhou Fan, Sergio A. Quezada et al. The Journal of Experimental Medicine profile →
  67. Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy
    2018 182 citations Sangeeta Goswami, Jan Zhang et al. profile →

Peers

James P. Allison
Comparison fields: 5 of 191
  • Immunology 50.0k
  • Oncology 39.1k
  • Molecular Biology 13.1k
  • Pulmonary and Respiratory Medicine 5.9k
  • Genetics 5.1k
Replace Gordon J. Freeman with:
Gordon J. Freeman United States
Mark J. Smyth Australia
Suzanne L. Topalian United States
Arlene H. Sharpe United States
Lieping Chen United States
Drew M. Pardoll United States
Robert D. Schreiber United States
Jedd D. Wolchok United States
Lloyd J. Old United States
Jacques Banchereau United States
Gordon J. Freeman United States View profile →
Citations per field, relative to James P. Allison
James P. Allison · 1×
Citations per year, relative to James P. Allison
James P. Allison · 1×

Countries citing papers authored by James P. Allison

Since Specialization
Citations

This map shows the geographic impact of James P. Allison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James P. Allison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James P. Allison more than expected).

Fields of papers citing papers by James P. Allison

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James P. Allison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James P. Allison. The network helps show where James P. Allison may publish in the future.

Co-authorship network of co-authors of James P. Allison

This figure shows the co-authorship network connecting the top 25 collaborators of James P. Allison. A scholar is included among the top collaborators of James P. Allison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James P. Allison. James P. Allison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner
2019 ·Cancer Immunology Research ·Lewis Z. Shi, Sangeeta Goswami, Tihui Fu, Baoxiang Guan, Jianfeng Chen, Liangwen Xiong, Jan Zhang, Derek Ng Tang, Xuejun Zhang, Luis M. Vence, Jorge Blando, James P. Allison, (unknown), Jianjun Gao, Padmanee Sharma
35
2
Characterization and Comparison of GITR Expression in Solid Tumors
2019 ·Clinical Cancer Research ·Luis M. Vence, Samantha Bucktrout, Irina Fernandez Curbelo, Jorge Blando, (unknown), (unknown), John Lin, (unknown), Edward Pascua, Tao Sai, Javier Chaparro‐Riggers, Sumit K. Subudhi, Jorge Scutti, (unknown), Hao Zhao, Shalini S. Yadav, Anirban Maitra, Ignacio I. Wistuba, James P. Allison, Padmanee Sharma
38
3
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers breakdown →
2018 ·Clinical Cancer Research ·Anu Sharma, Sumit K. Subudhi, Jorge Blando, Jorge Scutti, Luis M. Vence, Jennifer A. Wargo, James P. Allison, Antoni Ribas, Padmanee Sharma
266
4
ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40–Mediated Tumor Rejection
2016 ·Cancer Research ·Todd C. Metzger, Hua Long, Shobha Potluri, Thomas Pertel, Samantha L. Bailey-Bucktrout, John Lin, Tihui Fu, Padmanee Sharma, James P. Allison, (unknown)
49
5
Ablation of B7-H3 but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer
2015 ·Cancer Immunology Research ·Katharina Kreymborg, Stefan Haak, Rajmohan Murali, Joyce Wei, Rebecca Waitz, Georg Gasteiger, Peter A. Savage, Marcel R.M. van den Brink, James P. Allison
30
6
Cytotoxic T Lymphocyte Antigen-4 Blockade Enhances Antitumor Immunity by Stimulating Melanoma-Specific T-cell Motility
2014 ·Cancer Immunology Research ·Tsvetelina Pentcheva‐Hoang, Tyler R. Simpson, Welby Montalvo-Ortiz, James P. Allison
63
7
Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin
2013 ·The Journal of Experimental Medicine ·Michael A. Curran, Theresa L. Geiger, (unknown), Myoungjoo Kim, Steven L. Reiner, Aymen Al‐Shamkhani, Joseph C. Sun, James P. Allison
134
8
Aire-Dependent Thymic Development of Tumor-Associated Regulatory T Cells breakdown →
2013 ·Science ·Sven Malchow, Daniel S. Leventhal, Saki Nishi, (unknown), (unknown), Gladell P. Paner, (unknown), Chulho Kang, (unknown), James P. Allison, Nicholas D. Socci, Peter A. Savage
251
9
Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients
2013 ·Cancer Immunology Research ·Shigehisa Kitano, Takemasa Tsuji, (unknown), Daniel Hirschhorn-Cymerman, Chrisann Kyi, Zhenyu Mu, James P. Allison, Sacha Gnjatic, Jianda Yuan, Jedd D. Wolchok
96
10
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma breakdown →
2013 ·The Journal of Experimental Medicine ·Tyler R. Simpson, Fubin Li, Welby Montalvo-Ortiz, Manuel A. Sepúlveda, Katharina Bergerhoff, Frederick Arce, Claire Roddie, Jake Y. Henry, Hideo Yagita∥, Jedd D. Wolchok, Karl S. Peggs, Jeffrey V. Ravetch, James P. Allison, Sergio A. Quezada
1093
11
Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy
2013 ·Cancer Immunology Research ·Derek Ng Tang, Yu Shen, Jingjing Sun, Sijin Wen, Jedd D. Wolchok, Jianda Yuan, James P. Allison, Padmanee Sharma
146
12
Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Anti–CTLA-4 Therapy
2011 ·Cancer Research ·Rebecca Waitz, Stephen B. Solomon, Elena N. Petre, Anne E. Trumble, Marcella Fassò, Larry Norton, James P. Allison
210
13
Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals
2010 ·Clinical Cancer Research ·(unknown), Hiroyoshi Nishikawa, Daisuke Muraoka, Linan Wang, Takuro Noguchi, Eiichi Sato, Satoshi Kondo, James P. Allison, Shimon Sakaguchi, Lloyd J. Old, Takuma Kato, Hiroshi Shiku
106
14
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts breakdown →
2010 ·The Journal of Experimental Medicine ·Sergio A. Quezada, Tyler R. Simpson, Karl S. Peggs, Taha Merghoub, Jelena Vider, Xiaozhou Fan, Ronald G. Blasberg, Hideo Yagita∥, Pawel Muranski, Paul A. Antony, Nicholas P. Restifo, James P. Allison
635
15
Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial breakdown →
2010 ·Clinical Cancer Research ·Bradley Curtis Carthon, Jedd D. Wolchok, Jianda Yuan, Ashish M. Kamat, Derek S. Ng Tang, Jingjing Sun, Geoffrey Y. Ku, Patricia Troncoso, Christopher J. Logothetis, James P. Allison, Padmanee Sharma
358
16
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies breakdown →
2009 ·The Journal of Experimental Medicine ·Karl S. Peggs, Sergio A. Quezada, Cynthia A. Chambers, Alan J. Korman, James P. Allison
726
17
Tumor Vaccines Expressing Flt3 Ligand Synergize with CTLA-4 Blockade to Reject Preimplanted Tumors
2009 ·Cancer Research ·Michael A. Curran, James P. Allison
110
18
Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function
2007 ·Clinical Cancer Research ·Peter E. Fecci, Hidenobu Ochiai, Duane A. Mitchell, Peter M. Grossi, (unknown), Gary E. Archer, Thomas J. Cummings, James P. Allison, Darell D. Bigner, John H. Sampson
265
19
Inducible costimulator is required for type 2 antibody isotype switching but not T helper cell type 2 responses in chronic nematode infection
2005 ·Proceedings of the National Academy of Sciences ·P’ng Loke, Xingxing Zang, (unknown), Rebecca Waitz, Richard M. Locksley, Judith E. Allen, James P. Allison
20
20
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma breakdown →
2003 ·Proceedings of the National Academy of Sciences ·Giao Q. Phan, James Chih‐Hsin Yang, Richard M. Sherry, Patrick Hwu, Suzanne L. Topalian, Douglas J. Schwartzentruber, Nicholas P. Restifo, Leah Haworth, Claudia A. Seipp, (unknown), Kathleen E. Morton, Sharon Mavroukakis, Paul H. Duray, Seth M. Steinberg, James P. Allison, Thomas A. Davis, Steven A. Rosenberg
1234

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

You can learn more about the impact of James P. Allison by visiting their Pantheon page.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gordon J. Freeman Breakdown of academic impact, for papers by Mark J. Smyth Breakdown of academic impact, for papers by Suzanne L. Topalian Breakdown of academic impact, for papers by Arlene H. Sharpe Breakdown of academic impact, for papers by Lieping Chen Breakdown of academic impact, for papers by Drew M. Pardoll Breakdown of academic impact, for papers by Robert D. Schreiber Breakdown of academic impact, for papers by Jedd D. Wolchok Breakdown of academic impact, for papers by Lloyd J. Old Breakdown of academic impact, for papers by Jacques Banchereau
Rankless by CCL
2026